Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis

Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010

(2014) MerriKay Oleen-Burkey et al.   BMC Neurology

Immunomodulation neuroprotection and remyelination – The fundamental therapeutic effects of glatiramer acetate: A critical review

(2014) Rina Aharoni   JOURNAL OF AUTOIMMUNITY

A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial

(2014) Tjalf Ziemssen et al.   JOURNAL OF NEUROLOGY

Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense “black holes”: a post hoc magnetic resonance imaging analysis

(2014) Robert Zivadinov et al.   JOURNAL OF NEUROLOGY

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study

(2014) P. O'Connor et al.   NEUROLOGY

Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate

(2014) Olga G Kulakova et al.   PHARMACOGENOMICS

Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic

(2014) Fadi Towfic et al.   PLoS One

The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis

(2014) Sara J. Ireland et al.   JAMA Neurology

Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study

(2014) Josep Darbà et al.   JOURNAL OF MEDICAL ECONOMICS

How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider

(2013) Huub Schellekens et al.   AAPS Journal

Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis

(2013) Omar Khan et al.   ANNALS OF NEUROLOGY

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

(2013) Fred D. Lublin et al.   ANNALS OF NEUROLOGY

Pharmacogenomics of interferon beta and glatiramer acetate response: A review of the literature

(2013) Sunil Mahurkar et al.   AUTOIMMUNITY REVIEWS

Glatiramer Acetate: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis and in Delaying the Onset of Clinically Definite Multiple Sclerosis

(2013) Lesley J. Scott   CNS DRUGS

Long-Term Effects of Exposure to Disease-Modifying Drugs in the Offspring of Mothers with Multiple Sclerosis: A Retrospective Chart Review

(2013) Yara D. Fragoso et al.   CNS DRUGS

Gene expression analysis reveals functional pathways of glatiramer acetate activation

(2013) Shlomo Bakshi et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial

(2013) Douglas L. Arnold et al.   JOURNAL OF NEUROLOGY

HLA DR and DQ alleles and haplotypes associated with clinical response to glatiramer acetate in multiple sclerosis

(2013) Suhayl Dhib-Jalbut et al.   Multiple Sclerosis and Related Disorders

The mechanism of action of glatiramer acetate in multiple sclerosis and beyond

(2012) Rina Aharoni   AUTOIMMUNITY REVIEWS

Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study

(2012) Marta Giannini et al.   BMC Neurology

Cortical lesions in multiple sclerosis: inflammation versus neurodegeneration

(2012) H. Lassmann   BRAIN

The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis

(2012) Yara Dadalti Fragoso et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

Benefit–Risk Analysis of Glatiramer Acetate for Relapsing-Remitting and Clinically Isolated Syndrome Multiple Sclerosis

(2012) Nawab Qizilbash et al.   CLINICAL THERAPEUTICS

Glatiramer acetate for treatment of relapsing–remitting multiple sclerosis

(2012) Kenneth P Johnson   Expert Review of Neurotherapeutics

Multiple sclerosis and pregnancy: therapeutic considerations

(2012) Maria K. Houtchens et al.   JOURNAL OF NEUROLOGY

Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome

(2012) Giancarlo Comi et al.   Multiple Sclerosis Journal

Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review

(2012) E. Lu et al.   NEUROLOGY

Disease-Modifying Therapy of Pediatric Multiple Sclerosis

(2012) Tanuja Chitnis   Neurotherapeutics

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiple sclerosis and pregnancy: experience from a nationwide database in Germany

(2012) Kerstin Hellwig et al.   Therapeutic Advances in Neurological Disorders

Glatiramer Acetate in the Treatment of Multiple Sclerosis

(2011) Patrice H. Lalive et al.   CNS DRUGS

Distinct pathological patterns in relapsing–remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate

(2011) Rina Aharoni et al.   JOURNAL OF AUTOIMMUNITY

Recent insights into the mechanism of action of glatiramer acetate

(2011) Mrinalini Kala et al.   JOURNAL OF NEUROIMMUNOLOGY

Interferon  -1b and glatiramer acetate effects on permanent black hole evolution

(2011) M. Filippi et al.   NEUROLOGY

Comparative Long-Term Preclinical Safety Evaluation of Two Glatiramoid Compounds (Glatiramer Acetate, Copaxone®, and TV-5010, Protiramer) in Rats and Monkeys

(2011) Yuval Ramot et al.   TOXICOLOGIC PATHOLOGY

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis

(2011) Aaron Boster et al.   Therapeutic Advances in Neurological Disorders

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis

(2010) Giancarlo Comi et al.   ANNALS OF NEUROLOGY

Multiple Sclerosis Therapies in Pediatric Patients With Refractory Multiple Sclerosis

(2010) E. Ann Yeh et al.   ARCHIVES OF NEUROLOGY

Glatiramer acetate-reactive T lymphocytes regulate oligodendrocyte progenitor cell number in vitro: Role of IGF-2

(2010) Y. Zhang et al.   JOURNAL OF NEUROIMMUNOLOGY

Population structure and HLA DRB1*1501 in the response of subjects with multiple sclerosis to first-line treatments

(2010) Robert Gross et al.   JOURNAL OF NEUROIMMUNOLOGY

Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes

(2010) Heidi J. Salminen et al.   JOURNAL OF NEUROLOGY

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

(2010) C. Ford et al.   Multiple Sclerosis Journal

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis

(2010) Kenneth Johnson   Therapeutics and Clinical Risk Management

Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis

(2009) Jane Castelli-Haley et al.   ADVANCES IN THERAPY

The relation between inflammation and neurodegeneration in multiple sclerosis brains

(2009) Josa M. Frischer et al.   BRAIN

Linkage between immunomodulation, neuroprotection and neurogenesis

(2009) R. Aharoni et al.   DRUG NEWS & PERSPECTIVES

The glatiramoid class of immunomodulator drugs

(2009) Haim Varkony et al.   EXPERT OPINION ON PHARMACOTHERAPY

Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate

(2009) Ruth Arnon et al.   JOURNAL OF NEURAL TRANSMISSION

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

(2009) G Comi et al.   LANCET

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study

(2009) C Weber-Schoendorfer et al.   Multiple Sclerosis Journal

Efficacy of treatment of MS with IFN -1b or glatiramer acetate by monthly brain MRI in the BECOME study

(2009) D. Cadavid et al.   NEUROLOGY

MRI ASANOUTCOMEIN MULTIPLE SCLEROSIS CLINICAL TRIALS

(2009) M. P. Sormani et al.   NEUROLOGY

Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate

(2009) V. Skihar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Glatiramer acetate versus interferon beta-1a for subcutaneous administration: Comparison of outcomes among multiple sclerosis patients

(2008) Jane Castelli-Haley et al.   ADVANCES IN THERAPY

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY

Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis

(2008) R. Aharoni et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA